Neurocrine (NBIX) Price & Analysis

Compare

1,400 Followers

NBIX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$84.23 - $157.98

Previous CloseN/A

Volume209.65K

Average Volume (3M)917.37K

Market Cap

$12.41B

Enterprise Value$12.78B

Total Cash (Recent Filing)$943.50M

Total Debt (Recent Filing)$447.50M

Price to Earnings (P/E)42.6

Beta0.61

Next Earnings

Aug 05, 2025

EPS Estimate

0.98

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.08

Shares Outstanding98,965,820

10 Day Avg. Volume887,185

30 Day Avg. Volume917,368

Financial Highlights & Ratios

PEG Ratio-3.98

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio25.45

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue1.40

Enterprise Value/Gross Profit5.39

Enterprise Value/Ebitda5.44

Forecast

1Y Price Target

$160.25

Price Target Upside25.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering21

Neurocrine News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe clinical profile for NBI-568 is viewed positively, boosting confidence in progressing to Phase 3 trials.

Product LaunchCrenessity's efficacy and ease of use have led to early sales and adoption, indicating a path for growth.

Sales PerformanceInvestors will be highly pleased with 1Q25 Ingrezza sales of $545M, which exceeded expectations.

Bears Say

EarningsNon-GAAP EPS of $0.70 was below consensus due to higher-than-expected spending.

Growth ChallengesThe Ingrezza growth debate - slower but still robust: NBIX reaffirmed 2025 Ingrezza growth of +8-12% due to a higher base effect, increased competitive pressure, payer-related challenges, and sales force expansion & disruption.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.10% Insiders

28.04% Mutual Funds

26.30% Other Institutional Investors

16.77% Public Companies and Individual Investors

Detailed Ownership Overview >

NBIX FAQ

What was Neurocrine Biosciences’s price range in the past 12 months?

Neurocrine Biosciences lowest stock price was $84.23 and its highest was $157.98 in the past 12 months.

What is Neurocrine Biosciences’s market cap?

Neurocrine Biosciences’s market cap is $12.41B.

When is Neurocrine Biosciences’s upcoming earnings report date?

Neurocrine Biosciences’s upcoming earnings report date is Aug 05, 2025 which is in 33 days.

How were Neurocrine Biosciences’s earnings last quarter?

Neurocrine Biosciences released its earnings results on May 05, 2025. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.535 by -$0.455.

Is Neurocrine Biosciences overvalued?

According to Wall Street analysts Neurocrine Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neurocrine Biosciences pay dividends?

Neurocrine Biosciences does not currently pay dividends.

What is Neurocrine Biosciences’s EPS estimate?

Neurocrine Biosciences’s EPS estimate is 0.98.

How many shares outstanding does Neurocrine Biosciences have?

Neurocrine Biosciences has 98,965,820 shares outstanding.

What happened to Neurocrine Biosciences’s price movement after its last earnings report?

Neurocrine Biosciences reported an EPS of $0.08 in its last earnings report, missing expectations of $0.535. Following the earnings report the stock price went up 8.355%.

Which hedge fund is a major shareholder of Neurocrine Biosciences?

Currently, no hedge funds are holding shares in NBIX

Neurocrine Stock Smart Score

Outperform

Fundamentals

Return on Equity

12.43%

Trailing 12-Months

Asset Growth

6.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for neurological, endocrine, and psychiatric disorders. Founded in 1992 and headquartered in San Diego, California, the company is committed to addressing unmet medical needs through its proprietary drug discovery platform and a robust pipeline of therapeutic candidates. Neurocrine's flagship product is INGREZZA (valbenazine), the first FDA-approved medication for the treatment of tardive dyskinesia, a movement disorder. Additionally, the company has other products and candidates targeting conditions such as Parkinson's disease, endometriosis, and congenital adrenal hyperplasia.

NBIX Company Deck

NBIX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected strong performance in new patient starts for INGREZZA and a successful launch of CRENESSITY, highlighting significant achievements in R&D and financial strength. However, challenges in reauthorization and the impact of the Inflation Reduction Act were noted, affecting reimbursement dynamics and sales. Despite these challenges, the company remains well-positioned for future growth.Read More>

NBIX Stock 12 Month Forecast

Average Price Target

$160.25

▲(25.20%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","127":"$127","149":"$149","171":"$171","193":"$193"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$192.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$160.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,127,149,171,193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.56,129.74769230769232,134.9353846153846,140.12307692307692,145.31076923076924,150.49846153846153,155.68615384615384,160.87384615384616,166.06153846153848,171.24923076923076,176.43692307692308,181.62461538461537,186.81230769230768,{"y":192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.56,127.30538461538461,130.05076923076922,132.79615384615386,135.54153846153847,138.28692307692307,141.03230769230768,143.77769230769232,146.52307692307693,149.26846153846154,152.01384615384615,154.75923076923078,157.5046153846154,{"y":160.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,124.56,123.82461538461538,123.08923076923077,122.35384615384615,121.61846153846155,120.88307692307693,120.14769230769231,119.41230769230769,118.67692307692307,117.94153846153846,117.20615384615385,116.47076923076924,115.73538461538462,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >